CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 277 enrolled
Drug / intervention
MRSA Nasal Swab PCRother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06272994
NCT06272994N/ACompleted

Swab Testing to Optimize Pneumonia Treatment With Empiric Vancomycin (STOP-Vanc)

Vanderbilt University Medical Center·interventional·Posted Feb 22, 2024·Updated Feb 27, 2026

In Brief

A clinical study evaluating MRSA Nasal Swab PCR for Community-acquired Pneumonia. Completed, enrolled 277 participants across 1 site.

Detailed Summary

This is a single center, pragmatic, randomized clinical trial (pRCT) examining whether reporting the results of a negative rapid PCR back to the provider via a pager alert results in decreased vancomycin utilization for critically ill adults with community-acquired pneumonia when compared with usual care.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20252026
First PostedFeb 22, 2024
Enrollment StartApr 3, 2024
Primary CompletionFeb 4, 2025
Study CompletionFeb 27, 2025
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 2.4 years ago

Interventions

MRSA Nasal Swab PCRother

For the subjects assigned to the intervention group who have a negative MRSA nasal swab PCR result, providers will receive a pager alert which inform them of the negative result and will direct clinicians to clinical guidance recommending clinicians to discontinue vancomycin, if clinically appropriate.